Baseline Demographics and Clinical Characteristics of the Canagliflozin Cohort.

CCAE, Commercial Claims and Encounters; CDM, Clinformatics® Data Mart; EHR, electronic health record; EMR, electronic medical record; JMDC, Japan medical data center; MDCD, multi-state Medicaid database; MDCR, Medicare supplemental; NA, not available; SD, standard deviation. a Select comorbidities and concomitant medications are those with a prevalence of at least 20% in any treatment cohort. Concomitant medications exclude those that were evaluated in this study (i.e., canagliflozin, dapagliflozin, empagliflozin, liraglutide, and sitagliptin). (XLSX)